New Stock News | Biotechnology startup company Earendil Labs is planning to go public in Hong Kong with a potential fundraising of up to $500 million.

According to information from sources quoted by the media, biotech startup Earendil Labs is considering listing in Hong Kong and is working with CICC and Morgan Stanley to arrange a stock offering, with a potential financing size of up to $500 million (approximately HK$39 billion). Currently, Earendil, CICC, and Morgan Stanley have not responded to requests for comments. Information shows that Earendil Labs is an AI-driven biotech company focused on developing next-generation innovative biopharmaceuticals for treating autoimmune diseases, cancer, and other unmet medical needs. By integrating advanced machine learning, generative protein engineering, and high-throughput experimental technology, Earendil Labs and its affiliate Huashen Zhidu are committed to optimizing the drug discovery and research process to significantly accelerate drug development. In terms of partnerships, Earendil has collaborated with companies such as Sanofi, including a collaboration project for autoimmune and inflammatory diseases announced in January. In February, Earendil reached an agreement with the Hong Kong-listed WUXI XDC (02268) on cancer therapy technology. On March 12, the company announced another collaboration with WUXI BIO (02269).